Physician profile
Darin Gray
NPI 1619325990
$16,171.75
in general payments reported to CMS, 2019-2025
28 companies · $5,048 in 2025
The $5,048 reported for 2025 was more than what 98% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,477 · 2022: $3,058 · 2023: $3,537 · 2024: $2,052 · 2025: $5,048.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $563.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,073.07 |
| Education | $563.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,186.20 | 2021-2025 | |
| Ucb, INC. | $1,917.99 | 2021-2025 | Bimzelx, Cimzia |
| Leo Pharma INC. | $1,853.49 | 2021-2025 | Adbry, Anzupgo |
| Janssen Biotech, INC. | $1,576.01 | 2022-2025 | Tremfya, Simponi Aria |
| Regeneron Healthcare Solutions, INC. | $1,294.97 | 2021-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $959.68 | 2021-2025 | Ilumya, Blu-U |
| Pfizer INC. | $901.78 | 2021-2025 | |
| Genzyme Corporation | $816.06 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $662.39 | 2022-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $573.73 | 2021-2025 | |
| Lilly USA, LLC | $463.16 | 2021-2025 | Ebglyss, Taltz, Olumiant |
| Amgen INC. | $435.72 | 2021-2025 | Otezla, Otezla |
| Incyte Corporation | $334.55 | 2021-2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $268.52 | 2023-2025 | Zoryve |
| Galderma Laboratories, L.P. | $242.19 | 2021-2025 | Nemluvio |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $197.94 | 2022-2024 | Vtama |
| Sanofi-Aventis U.S. LLC | $129.17 | 2021-2023 | |
| Hill Dermaceuticals, INC. | $60.39 | 2024-2025 | Tolak |
| Organon LLC | $58.63 | 2025 | Vtama |
| Sandoz INC. | $56.50 | 2023-2024 | Hyrimoz |
| Cipher Pharmaceuticals US LLC | $43.68 | 2025 | Spinosad, Natroba |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $32.55 | 2021-2025 | Cabtreo, Siliq, Jublia |
| Verrica Pharmaceuticals INC. | $25.20 | 2025 | Ycanth |
| Biofrontera INC. | $20.83 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
| Mission Pharmacal Company | $19.29 | 2021 | |
| Journey Medical Corporation | $15.24 | 2025 | |
| Helsinn Therapeutics (U.S.), INC. | $14.24 | 2022 | |
| Vyne Pharmaceuticals INC. | $11.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darin Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.